CR Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
CR Therapeutics - overview
Established
2023
Location
Chengdu, Sichuan, China
Primary Industry
Biotechnology
About
Based in Chengdu, China and founded in 2023, Chengdu CR Therapeutics Technology Co. , Ltd. , trading as CR Therapeutics, is a biopharmaceutical service provider, focusing on the research and development of next-generation universal cell therapy products, including novel universal therapeutic cell vaccines and in vivo CAR-T. In May 2026, CR Therapeutics raised nearly CNY 100 million in venture funding co-led by Chengdu Science and Technology Venture Capital Group and YuanBio Venture, with participation from Chengdu Renyou Investment, Peakview Capital, Legend Capital and other investors.
The company possesses two major platform technologies: novel universal therapeutic antitumor vaccines and next-generation universal CAR-T cell therapy, both with unique and innovative scientific principles, and their corresponding products have strong international competitiveness. The company’s revenue is generated by providing next-generation universal cell therapy products. The company will use the latest funding to expand the company's core pipeline for clinical trials.
Current Investors
Kushan Industrial Research Institute Management, Legend Capital, Chengdu Science and Technology Venture Capital Group
Primary Industry
Biotechnology
Sub Industries
Biotechnology, Biopharmaceuticals, Pharmaceuticals, Pharmaceutical Research & Development
Verticals
HealthTech
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.